Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation
Cochrane Database of Systematic Reviews, 2008•cochranelibrary.com
Background Patients undergoing hematopoietic stem cell transplantation (HSCT) and those
with lymphoproliferative disorders (LPD) have a higher incidence of infections due to
secondary hypogammaglobulinemia. One approach is the prophylactic administration of
intravenous immunoglobulins (IVIG). Randomized controlled trials (RCTs) showed
conflicting results in terms of type, schedule, dose and hematological patients benefiting
from IVIG. We therefore performed a systematic review and meta‐analysis to evaluate the …
with lymphoproliferative disorders (LPD) have a higher incidence of infections due to
secondary hypogammaglobulinemia. One approach is the prophylactic administration of
intravenous immunoglobulins (IVIG). Randomized controlled trials (RCTs) showed
conflicting results in terms of type, schedule, dose and hematological patients benefiting
from IVIG. We therefore performed a systematic review and meta‐analysis to evaluate the …
Background
Patients undergoing hematopoietic stem cell transplantation (HSCT) and those with lymphoproliferative disorders (LPD) have a higher incidence of infections due to secondary hypogammaglobulinemia. One approach is the prophylactic administration of intravenous immunoglobulins (IVIG). Randomized controlled trials (RCTs) showed conflicting results in terms of type, schedule, dose and hematological patients benefiting from IVIG. We therefore performed a systematic review and meta‐analysis to evaluate the role of IVIG in these patients.
Objectives
To determine whether prophylaxis with IVIG reduces mortality or affects other outcomes in patients with hematological malignancies.
cochranelibrary.com